The $100 million IDEAS (Imaging Dementia — Evidence for Amyloid Scanning) Study is working closely with researchers and government officials to add three additional studies to the main project, where […]

Taconic Biosciences is improving its services to Alzheimer’s disease researchers — creating a ready-to-use stock of an important mouse model of the disease. Earlier procedures forced researchers […]

The state of New York lacks effective measures for preventing diabetes, which is fueling a dramatic increase in Alzheimer’s disease. So says a new document, “Unprevented Diabetes Means Unnecessary Alzheimer’s,” […]

Axsome Therapeutics’ investigational drug AXS-05 was recently granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of agitation in patients […]

A new study found personalized music therapy helped decrease antipsychotic and anti-anxiety medication use, as well as improve dementia symptoms, in people living with Alzheimer’s disease […]

In a recent Morbidity and Mortality Weekly Report from the Centers for Disease Control and Prevention (CDC), researchers show that deaths due to Alzheimer’s disease increased […]

Two surveys released today — the start of Alzheimer’s disease month — examine the emotional toll the condition places on caregivers, and their need for greater support. […]

Insightec’s new platform, Exablate Neuro, is to be a part of the first-ever clinical trial (NCT02986932) evaluating the safety and feasibility of opening the blood-brain barrier […]

The National Institutes of Health (NIH) has awarded Pain Therapeutics a $1.7 million research grant to study PTI-125 as a potential treatment for Alzheimer’s disease. ReadMore…

Otsuka America Pharmaceutical and Avanir Pharmaceuticals are working with southern New Jersey educational administrators to create specialists who can help Alzheimer’s patients and their families navigate the care continuum. […]

Epileptic-seizure-like activity in a brain region called the hippocampus may contribute to the development of Alzheimer’s, according to a case study involving two patients. ReadMore…

Promising data from Sangamo Therapeutics‘ research programs, including Alzheimer’s disease, were recently announced. ReadMore…

Acadia Pharmaceuticals plans to start a Phase 3 clinical program to explore the effect of Nuplazid (pimavanserin) in Alzheimer’s disease patients with psychosis. The medication was […]

A new DNA vaccine protects against accumulation of toxic proteins in Alzheimer’s disease, according to new research. ReadMore…

Gevervon Biopharmaceuticals Recently shared a previously exclusive list of 84 genes related to Alzheimer’s sickness which might be modulated by way of their investigational remedy GM6. […]